MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592863 | Name: Amphocil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Amphocil is used to treat patients with invasive fungal infection.

Chemical Structure

Amphocil
Amphocil
CAS#120895-52-5

Theoretical Analysis

MedKoo Cat#: 592863

Name: Amphocil

CAS#: 120895-52-5

Chemical Formula: C74H119NO21S

Exact Mass: 1389.7995

Molecular Weight: 1390.81

Elemental Analysis: C, 63.91; H, 8.62; N, 1.01; O, 24.16; S, 2.31

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Amphocil; Amphotericin B cholesteryl sulfate
IUPAC/Chemical Name
Amphotericin B, compd. with (3beta)-cholest-5-en-3-yl hydrogen sulfate (1:1)
InChi Key
PCTMTFRHKVHKIS-BMFZQQSSSA-N
InChi Code
InChI=1S/C47H73NO17.C27H46O4S/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56;1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(31-32(28,29)30)13-15-26(20,4)25(22)14-16-27(23,24)5/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60);9,18-19,21-25H,6-8,10-17H2,1-5H3,(H,28,29,30)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+;/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+;19-,21+,22+,23-,24+,25+,26+,27-/m01/s1
SMILES Code
C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](O[C@H]2[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O2)C[C@H]3[C@H](C(O)=O)[C@@H](O)C[C@](C[C@@H](O)C[C@@H](O)[C@H](O)CC[C@@H](O)C[C@@H](O)CC(O[C@@H](C)[C@H](C)[C@@H]1O)=O)(O)O3.C[C@@H]([C@H]4CC[C@@H]5[C@]4(C)CC[C@H]6[C@H]5CC=C7[C@]6(C)CC[C@H](OS(=O)(O)=O)C7)CCCC(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,390.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Azanza JR, Sádada B, Reis J. Liposomal formulations of amphotericin B: differences according to the scientific evidence. Rev Esp Quimioter. 2015 Dec;28(6):275-81. Review. PubMed PMID: 26621170. 2: Adler-Moore JP, Gangneux JP, Pappas PG. Comparison between liposomal formulations of amphotericin B. Med Mycol. 2016 Mar;54(3):223-31. doi: 10.1093/mmy/myv111. Epub 2016 Jan 14. Review. PubMed PMID: 26768369. 3: Houdek MT, Greenwood-Quaintance KE, Morrey ME, Patel R, Hanssen AD. Elution of High Dose Amphotericin B Deoxycholate From Polymethylmethacrylate. J Arthroplasty. 2015 Dec;30(12):2308-10. doi: 10.1016/j.arth.2015.06.002. Epub 2015 Jun 11. PubMed PMID: 26162513. 4: Berman J. Amphotericin B formulations and other drugs for visceral leishmaniasis. Am J Trop Med Hyg. 2015 Mar;92(3):471-3. doi: 10.4269/ajtmh.14-0743. Epub 2014 Dec 15. PubMed PMID: 25510726; PubMed Central PMCID: PMC4350529. 5: Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis. Antimicrob Agents Chemother. 2004 Mar;48(3):1047-50. PubMed PMID: 14982807; PubMed Central PMCID: PMC353056. 6: Janout V, Schell WA, Thévenin D, Yu Y, Perfect JR, Regen SL. Taming Amphotericin B. Bioconjug Chem. 2015 Oct 21;26(10):2021-4. doi: 10.1021/acs.bioconjchem.5b00463. Epub 2015 Sep 10. PubMed PMID: 26340430. 7: Ohata Y, Tomita Y, Suzuki K, Maniwa T, Yano Y, Sunakawa K. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics. Drug Metab Pharmacokinet. 2015 Dec;30(6):400-9. doi: 10.1016/j.dmpk.2015.08.003. Epub 2015 Aug 28. PubMed PMID: 26645511. 8: Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant. 2000 Apr;25(8):879-84. PubMed PMID: 10808210. 9: Kaur L, Jain SK, Manhas RK, Sharma D. Nanoethosomal formulation for skin targeting of amphotericin B: an in vitro and in vivo assessment. J Liposome Res. 2015;25(4):294-307. doi: 10.3109/08982104.2014.995670. Epub 2014 Dec 30. PubMed PMID: 25547800. 10: Souza AC, Nascimento AL, de Vasconcelos NM, Jerônimo MS, Siqueira IM, R-Santos L, Cintra DO, Fuscaldi LL, Pires Júnior OR, Titze-de-Almeida R, Borin MF, Báo SN, Martins OP, Cardoso VN, Fernandes SO, Mortari MR, Tedesco AC, Amaral AC, Felipe MS, Bocca AL. Activity and in vivo tracking of Amphotericin B loaded PLGA nanoparticles. Eur J Med Chem. 2015 May 5;95:267-76. doi: 10.1016/j.ejmech.2015.03.022. Epub 2015 Mar 14. PubMed PMID: 25827397. 11: Asthana S, Gupta PK, Jaiswal AK, Dube A, Chourasia MK. Targeted chemotherapy of visceral leishmaniasis by lactoferrin-appended amphotericin B-loaded nanoreservoir: in vitro and in vivo studies. Nanomedicine (Lond). 2015;10(7):1093-109. doi: 10.2217/nnm.14.182. PubMed PMID: 25929567. 12: Stevens DA. Overview of amphotericin B colloidal dispersion (amphocil). J Infect. 1994 May;28 Suppl 1:45-9. Review. PubMed PMID: 8077690. 13: Kumar R, Sahoo GC, Pandey K, Das V, Das P. Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani. Drug Deliv. 2015 May;22(3):383-8. doi: 10.3109/10717544.2014.891271. Epub 2014 Mar 6. PubMed PMID: 24601828. 14: Chen YC, Su CY, Jhan HJ, Ho HO, Sheu MT. Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. Int J Nanomedicine. 2015 Dec 2;10:7265-74. doi: 10.2147/IJN.S95194. eCollection 2015. PubMed PMID: 26664117; PubMed Central PMCID: PMC4671761. 15: Santos CM, de Oliveira RB, Arantes VT, Caldeira LR, de Oliveira MC, Egito ES, Ferreira LA. Amphotericin B-loaded nanocarriers for topical treatment of cutaneous leishmaniasis: development, characterization, and in vitro skin permeation studies. J Biomed Nanotechnol. 2012 Apr;8(2):322-9. PubMed PMID: 22515084. 16: Shan-Bin G, Yue T, Ling-Yan J. Long-term sustained-released in situ gels of a water-insoluble drug amphotericin B for mycotic arthritis intra-articular administration: preparation, in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2015 Apr;41(4):573-82. doi: 10.3109/03639045.2014.884129. Epub 2014 Feb 7. PubMed PMID: 24502270. 17: Casa DM, Carraro TC, de Camargo LE, Dalmolin LF, Khalil NM, Mainardes RM. Poly(L-lactide) Nanoparticles Reduce Amphotericin B Cytotoxicity and Maintain Its In Vitro Antifungal Activity. J Nanosci Nanotechnol. 2015 Jan;15(1):848-54. PubMed PMID: 26328449. 18: Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents. 2000 Feb;13(4):243-8. PubMed PMID: 10755238. 19: Berman JD, Ksionski G, Chapman WL, Waits VB, Hanson WL. Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis. Antimicrob Agents Chemother. 1992 Sep;36(9):1978-80. PubMed PMID: 1416890; PubMed Central PMCID: PMC192218. 20: Azanza JR, Sádaba B, Gómez-Guíu A. [Pharmacology of the antifungals used in the treatment of aspergillosis]. Rev Iberoam Micol. 2014 Oct-Dec;31(4):255-61. doi: 10.1016/j.riam.2014.05.001. Epub 2014 Jun 21. Review. Spanish. PubMed PMID: 25442382.